Aduhelm (aducanumab) is the first new dementia drug treatment to come to market since 2003.
Featured news and events
In this four part series, Senju Joseph, a carer at the Dementia Respite care centre in Thrissur, India, documents his experience of navigating the catastrophic second COVID-19 wave.
ADI members in the African region took part in their first regional meeting of 2021 and since the COVID-19 pandemic began in early 2020.
The World Alzheimer Report 2020 has been awarded the European Healthcare Design (EHD) 2021 Award for Outstanding Contribution to Global Knowledge.
As the 74th World Health Assembly begins, ADI is sharing a statement submitted to the World Health Organization (WHO) and Member States.
ADI members in the European and Caribbean regions took part in the first regional meetings of 2021 and since the COVID-19 pandemic began in early 2020.
ADI is pleased to welcome 6 new member associations, as well as new members to the ADI board.
During the 60-minute meeting, the advisory panel discussed ADI's activities over the last year, as well as proposals for future avenues of research, including a working group to explore the impact of COVID-19 as a potential risk factor for accelerating dementia.
The ADI Council met on 30 March 2021 to discuss ADI's activities over 2020, new membership applications and more.
Phase II trial results found that donanemab slowed cognitive and functional decline in patients with early symptomatic Alzheimer's disease.